Assessment of Quality Standards and GMP Compliance of Pharmaceutical Formulations in the Indian Pharmaceutical Sector

The Indian pharmaceutical industry has evolved into one of the most dynamic and influential sectors of the global healthcare system. Often recognized as the “pharmacy of the world,” India supplies nearly 20% of the global demand for generic medicines and meets a substantial portion of vaccine requirements for developing nations. The country’s pharmaceutical sector has witnessed rapid expansion over the past two decades, driven by scientific innovation, policy support, and cost-efficient manufacturing. However, this remarkable growth also presents a critical responsibility—ensuring that pharmaceutical formulations consistently meet internationally accepted standards of quality, safety, and efficacy. Maintaining product quality is not merely a regulatory requirement but a moral and professional obligation of every manufacturer involved in drug production. Quality assurance and Good Manufacturing Practices (GMP) play a central role in safeguarding therapeutic consistency from raw material procurement to final product release. GMP compliance ensures that manufacturing processes are scientifically validated, adequately documented, and continuously monitored. Despite the existence of a comprehensive legal framework under the Drugs and Cosmetics Act (1940) and Rules (1945), as well as the provisions of Schedule M, challenges persist, particularly among small and medium-scale enterprises (SMEs), which form the backbone of India’s domestic pharmaceutical production. The regulatory framework in India aligns with several international standards such as the World Health Organization (WHO-GMP) guidelines and International Council for Harmonisation (ICH) Q10 pharmaceutical quality system. These frameworks promote a structured and risk-based approach to manufacturing that emphasizes preventive control, traceability, and documentation integrity. Nonetheless, non-compliance incidents, import alerts, and product recalls indicate that a segment of the industry continues to struggle with implementation consistency. Variations in infrastructure, inadequate staff training, and poor documentation practices remain major impediments to uniform GMP adoption across the sector. The Central Drugs Standard Control Organization (CDSCO), supported by State Drug Regulatory Authorities (SDRAs), is responsible for inspecting manufacturing sites, issuing licenses, and ensuring adherence to GMP standards. In recent years, regulatory bodies have intensified inspection frequencies and introduced reforms to modernize the compliance environment. The introduction of Schedule M (Amendment Draft 2023) and initiatives such as the Pharma Vision 2030 underscore the government’s commitment to raising manufacturing standards and harmonizing them with global benchmarks. Despite these efforts, achieving universal GMP compliance across more than 10,000 registered pharmaceutical units in India remains a formidable challenge. The implications of inadequate GMP adherence extend beyond commercial consequences—they directly influence patient safety, therapeutic efficacy, and the credibility of Indian medicines in the global market. Instances of regulatory warnings and import bans by agencies such as the USFDA and EMA have underscored the urgent need for continuous improvement in manufacturing quality systems. Conversely, globally reputed Indian firms that have successfully adopted robust Quality Management Systems (QMS) demonstrate that high compliance levels are attainable through investment in technology, training, and ethical leadership. The present study aims to assess the current status of GMP compliance and quality standards in the Indian pharmaceutical formulations sector. By analyzing available regulatory reports, inspection findings, and certification trends, the research identifies critical gaps and proposes actionable strategies to enhance compliance. The paper also explores the role of digital quality management, risk-based inspection models, and international harmonization as tools for ensuring sustainable quality improvement. In this context, assessing India’s GMP compliance is not merely an academic exercise but a vital step toward strengthening public health infrastructure and preserving the nation’s reputation as a trusted global medicine supplier. A robust quality framework—supported by policy enforcement, industry cooperation, and technological advancement—is essential for sustaining the reliability, safety, and effectiveness of Indian pharmaceutical products.

Figure 1: Growth of the Indian Pharmaceutical Sector (2015–2025)

The assurance of pharmaceutical quality and compliance with Good Manufacturing Practices (GMP) is a fundamental requirement for safeguarding public health and maintaining global trust in India’s drug supply. Given the diversity of manufacturing units and varying levels of regulatory maturity across the Indian pharmaceutical landscape, a systematic evaluation of GMP implementation becomes essential. This research is designed to provide a comprehensive understanding of the prevailing standards of quality and the extent of GMP compliance among Indian pharmaceutical formulation manufacturers.

The specific objectives of this study are as follows:

1. To assess the current level of GMP compliance among pharmaceutical formulation industries operating in India, including both large-scale manufacturers and small to medium enterprises (SMEs).
2. To identify and analyze the major deviations and deficiencies commonly reported during regulatory inspections conducted by national and international authorities such as CDSCO, WHO, and USFDA.
3. To examine the role of regulatory frameworks—including Schedule M, WHO-GMP, and ICH Q10—in shaping the quality management systems of Indian pharmaceutical companies.
4. To evaluate the impact of organizational factors, such as infrastructure, personnel training, documentation practices, and technological resources, on GMP adherence.
5. To propose evidence-based recommendations for strengthening the implementation of GMP and improving the overall quality assurance mechanisms within the Indian pharmaceutical sector.

By fulfilling these objectives, the study aims to bridge the gap between regulatory requirements and on-ground manufacturing practices, offering practical insights for policymakers, industry professionals, and academic researchers. The analysis not only contributes to understanding existing compliance levels but also serves as a framework for achieving sustainable quality improvement and global regulatory alignment.

3. METHODOLOGY

This study adopts a descriptive and analytical research design to evaluate the existing quality standards and the level of Good Manufacturing Practices (GMP) compliance in the Indian pharmaceutical formulations sector. The methodology combines both primary and secondary data sources, ensuring a comprehensive assessment of regulatory frameworks, inspection outcomes, and industrial practices.

3.1 Research Design

The research follows a mixed-method approach, incorporating both quantitative and qualitative analyses. Quantitative data were obtained from official reports, inspection summaries, and GMP certification databases, while qualitative information was derived from literature reviews, expert opinions, and policy documents. This combination enables a holistic understanding of the compliance landscape.

3.2 Data Sources

• Central Drugs Standard Control Organization (CDSCO) Inspection Reports and Annual Summaries

The Central Drugs Standard Control Organization (CDSCO) serves as the national regulatory authority in India, responsible for regulating pharmaceuticals, medical devices, and cosmetics under the Drugs and Cosmetics Act, 1940. Among its key functions, CDSCO conducts regular inspections of pharmaceutical manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP) and national quality standards.

CDSCO inspection reports provide detailed evaluations of manufacturing units, documenting adherence to GMP parameters, including:

• Facility infrastructure and environmental controls
• Equipment qualification and maintenance records
• Raw material procurement and storage conditions
• Batch production and quality control documentation
• Personnel training and hygiene practices
• Process validation, change control, and deviation management

Inspections are performed according to a risk-based approach, with high-risk facilities (such as those producing sterile injectables or high-value export formulations) receiving more frequent scrutiny. Reports categorize findings into critical, major, and minor non-conformities, allowing regulators to prioritize corrective actions.

Annual summaries published by CDSCO consolidate inspection outcomes across the country. These summaries typically include:

• Total number of facilities inspected, classified by state and scale (large, medium, small)
• Percentage of units found fully compliant, partially compliant, or non-compliant
• Most frequently observed deviations, such as incomplete documentation, inadequate validation, or personnel-related deficiencies
• Trends in GMP compliance over time, highlighting improvements or recurring challenges

For this study, CDSCO reports from 2020 to 2025 were analyzed to quantify compliance levels, identify common deficiencies, and assess the effectiveness of regulatory interventions. Data from annual summaries were used to construct tables and visual representations, including compliance distribution charts, non-conformity frequency tables, and comparisons between large-scale enterprises and SMEs. By systematically analyzing these reports, the study gains an evidence-based understanding of GMP implementation in India, highlighting both progress and areas requiring further intervention. CDSCO inspection reports thus serve as a primary and authoritative source for evaluating national pharmaceutical quality standards.

The World Health Organization (WHO) provides a globally recognized framework for Good Manufacturing Practices (GMP), ensuring that pharmaceutical products meet internationally accepted standards of quality, safety, and efficacy. WHO-GMP certification is particularly important for manufacturers that supply medicines to international markets, including low- and middle-income countries, under WHO prequalification programs. WHO-GMP certification lists include all pharmaceutical manufacturers that have successfully met the rigorous standards set by WHO inspectors. These lists are publicly available and provide key details such as:

• Name and location of the manufacturing facility
• Scope of certified products (e.g., oral solid dosage, injectables, vaccines)
• Date of certification and validity period
• Inspection outcomes highlighting any major or minor deficiencies identified during the certification process

Compliance records maintained by WHO track ongoing adherence to GMP requirements. These records detail:

• Frequency and outcomes of post-certification inspections
• Corrective actions implemented by the manufacturer in response to observed deviations
• Suspension or withdrawal of certification in cases of persistent non-compliance
• Trends in compliance over time, enabling identification of common challenges across manufacturers

For the Indian pharmaceutical sector, WHO-GMP certification is a critical marker of international quality recognition. Many large-scale Indian pharmaceutical companies, such as Sun Pharma, Dr. Reddy’s Laboratories, and Cipla, have successfully acquired WHO-GMP certification for a wide range of formulations. Conversely, most small and medium enterprises (SMEs) have limited WHO-GMP-certified products, often due to resource constraints, infrastructural limitations, and gaps in quality management systems.

In this study, WHO-GMP certification lists and compliance records from 2020 to 2025 were analyzed to:

• Determine the proportion of Indian manufacturing units holding international GMP certification
• Compare GMP adherence between large-scale manufacturers and SMEs
• Identify trends in certification uptake and ongoing compliance improvements

The data extracted from WHO-GMP lists were later visualized in a pie chart (Figure 3: Distribution of GMP-Certified Units in India), allowing for a clear representation of compliance across different scales of manufacturing units. These records thus serve as an authoritative source for assessing global-standard GMP implementation in the Indian pharmaceutical industry.

Figure 2: Distribution of GMP-Certified Units in India (2025)

The United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) are two of the most influential international regulatory authorities overseeing pharmaceutical manufacturing quality. Inspections conducted by these agencies are crucial for Indian pharmaceutical manufacturers aiming to export products to the U.S., European Union, and other regulated markets. These inspections focus on ensuring compliance with internationally recognized Good Manufacturing Practices (GMP) and verifying that the quality, safety, and efficacy of pharmaceutical products are consistently maintained.

USFDA inspections involve detailed on-site assessments of manufacturing units, including:

• Evaluation of quality management systems (QMS) and adherence to standard operating procedures (SOPs)
• Verification of process validation, batch documentation, and change control procedures
• Assessment of facility hygiene, environmental monitoring, and equipment qualification
• Review of personnel training programs and competency records

Post-inspection, USFDA issues detailed inspection classification reports, which may include:

• No Action Indicated (NAI): facility meets compliance standards
• Voluntary Action Indicated (VAI): minor deviations requiring corrective action
• Official Action Indicated (OAI): major deviations that could result in import alerts or enforcement actions

EMA inspections focus on compliance with EU GMP guidelines, emphasizing:

• Product-specific quality control, especially for sterile and high-risk formulations
• Data integrity and electronic records management
• Risk-based quality assessments and supplier audits

For Indian pharmaceutical companies, inspection outcomes from USFDA and EMA serve as benchmarks for international GMP compliance. Large-scale manufacturers typically maintain high compliance, reflected by NAI or minor VAI observations, while SMEs often face challenges leading to OAI observations. Reports from 2020 to 2025 were reviewed in this study to identify common deficiencies, evaluate compliance trends, and compare adherence between large enterprises and SMEs.

The data extracted from USFDA and EMA inspection reports were used to construct bar charts and tables illustrating:

• Compliance percentages of Indian manufacturing units
• Common non-conformities observed
• Trends in international regulatory recognition

By incorporating USFDA and EMA inspection findings, this study provides a global perspective on GMP compliance, complementing national CDSCO and WHO-GMP data. Such an integrated approach enables a comprehensive assessment of India’s pharmaceutical quality standards and identifies areas needing strategic improvements to meet international regulatory expectations.

Figure3: GMP inspection outcomes of Indian pharmaceutical units by USFDA and EMA (2020–2025)

• Pharmaceutical Export Promotion Council of India (Pharmexcil) Publications on Export Quality Standards

The Pharmaceutical Export Promotion Council of India (Pharmexcil), established under the Ministry of Commerce and Industry, Government of India, plays a pivotal role in promoting pharmaceutical exports while ensuring adherence to international quality standards. Pharmexcil serves as a bridge between Indian pharmaceutical manufacturers and global markets, facilitating trade, providing market intelligence, and advocating compliance with regulatory requirements.

Pharmexcil publications provide comprehensive insights into the quality expectations of importing countries, highlighting both mandatory and recommended standards for pharmaceutical exports. Key areas covered in these publications include:

• Regulatory compliance requirements for different export markets, including the U.S., European Union, Africa, and Asia
• Quality assurance guidelines, emphasizing Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and adherence to pharmacopeial standards
• Export performance reports, identifying top exporting companies, product categories, and geographic trends
• Inspection and certification trends, including WHO-GMP prequalification, USFDA compliance, and other international certifications required for market access

For Indian pharmaceutical manufacturers, Pharmexcil publications serve as a strategic resource for aligning production with international standards, ensuring that exported formulations meet the quality expectations of foreign regulatory authorities. The documents also provide guidance on common compliance pitfalls, such as documentation gaps, process validation deficiencies, and data integrity issues, which could hinder export approvals.

In this study, Pharmexcil reports from 2020 to 2025 were analyzed to:

1. Assess the overall compliance of Indian pharmaceutical exports with global quality standards
2. Identify trends in international certifications and GMP adherence among exporters
3. Correlate export performance with GMP compliance levels, highlighting areas for improvement among SMEs and large-scale manufacturers

The insights obtained from Pharmexcil publications were integrated with data from CDSCO, WHO-GMP, USFDA, and EMA to provide a comprehensive evaluation of India’s pharmaceutical quality landscape. These publications not only support quantitative analysis but also offer qualitative guidance for policymakers, manufacturers, and regulatory agencies to strengthen compliance mechanisms and enhance India’s reputation as a reliable supplier of high-quality pharmaceutical formulations.

Peer-Reviewed Articles, National Policy Documents, and Government Notifications (Schedule M, Amendment Draft 2023)

In addition to regulatory inspection reports and export data, the study relies on peer-reviewed literature, national policy documents, and official government notifications to provide a comprehensive understanding of GMP compliance and quality standards in the Indian pharmaceutical sector. These sources offer critical insights into regulatory frameworks, implementation challenges, and recent reforms aimed at enhancing manufacturing quality.

Peer-reviewed articles serve as an authoritative source for understanding both theoretical and applied aspects of GMP adherence. They provide empirical data on manufacturing practices, quality management systems, non-compliance trends, and the efficacy of regulatory interventions. By synthesizing findings from multiple studies, this research identifies recurring issues, such as documentation gaps, personnel training deficiencies, and process validation failures, which are prevalent across different scales of pharmaceutical units.

National policy documents, including reports published by the Ministry of Health and Family Welfare (MoHFW) and the Department of Pharmaceuticals, outline India’s strategic direction for the pharmaceutical sector. They detail objectives related to manufacturing quality, export promotion, and international regulatory alignment. For instance, the Pharma Vision 2030 initiative emphasizes infrastructure modernization, digital quality management adoption, and harmonization with global GMP standards, highlighting government-led efforts to improve compliance.

Schedule M (Amendment Draft 2023) represents a critical government notification that updates the national framework for Good Manufacturing Practices. Key changes include:

• Revised requirements for facility design, equipment validation, and environmental monitoring
• Strengthened emphasis on documentation practices, batch records, and electronic recordkeeping
• Mandatory risk-based quality management systems and periodic revalidation of processes
• Guidelines to harmonize Indian standards with WHO-GMP and ICH Q10 principles

In this study, Schedule M (Amendment Draft 2023) serves as the benchmark for evaluating domestic GMP compliance, while peer-reviewed literature and policy documents provide contextual and analytical support. By integrating these sources with CDSCO inspections, WHO-GMP records, USFDA and EMA reports, and Pharmexcil export data, the research achieves a multi-dimensional assessment of quality standards, enabling evidence-based recommendations for improving compliance across the Indian pharmaceutical industry.

3.3 Data Analysis

The data collected from multiple sources—including CDSCO inspection reports, WHO-GMP certification lists, USFDA and EMA inspection reports, Pharmexcil export publications, and peer-reviewed literature—were systematically organized, processed, and analyzed to evaluate GMP compliance and quality standards in Indian pharmaceutical formulations.

Data organization:

• Information was classified according to type of manufacturing unit: large-scale, medium-scale, and small-scale enterprises (SMEs).
• Compliance data were grouped by certification type, such as WHO-GMP, Schedule M, or international approvals.
• Non-compliance observations were categorized into key parameters, including documentation, equipment and facilities, personnel, validation, and quality control.

Quantitative analysis:

• Frequency distributions were calculated for each non-compliance category to identify common deficiencies across the sector.
• Compliance percentages were computed for large-scale versus SME units, enabling a comparative assessment of GMP adherence.
• Export volumes and certification status were correlated using tabular and graphical analyses to examine the relationship between GMP compliance and international market performance.

Qualitative analysis:

• Trends and patterns were identified through content analysis of inspection reports, regulatory notifications, and literature reviews.
• Recurrent issues, such as documentation gaps, inadequate validation, or personnel training deficiencies, were highlighted to understand systemic challenges in GMP implementation.
• Policy and regulatory changes, including Schedule M (Amendment Draft 2023) and digital quality management initiatives, were analyzed for their impact on compliance trends.

Visualization and interpretation:

• Data were represented using tables, bar graphs, allowing clear interpretation of compliance levels, non-conformity frequencies, and inspection outcomes.
• Comparative visuals were employed to illustrate differences between large-scale enterprises and SMEs, as well as trends over time from 2020 to 2025.
• Statistical summaries facilitated identification of critical areas for improvement, forming the basis for actionable recommendations.

This structured approach ensured a comprehensive, evidence-based assessment of GMP compliance, bridging national regulatory data with international standards, and providing a foundation for meaningful discussion and policy recommendations in subsequent sections.

3.4 Evaluation Criteria

To systematically assess Good Manufacturing Practice (GMP) compliance in the Indian pharmaceutical sector, this study employs a set of structured evaluation criteria derived from both national and international regulatory frameworks, including Schedule M (Drugs and Cosmetics Rules), WHO-GMP, and ICH Q10 guidelines. These criteria are designed to capture critical aspects of manufacturing quality, process control, and organizational practices.

Key Evaluation Parameters:

1. Quality Management System (QMS) and Documentation Practices
   • Presence of a formalized QMS and Standard Operating Procedures (SOPs)
   • Completeness and accuracy of batch manufacturing records
   • Traceability of raw materials, intermediates, and finished products
   • Record maintenance for deviations, complaints, and product recalls
2. Facility Design and Equipment
   • Adequacy of manufacturing space and layout to prevent cross-contamination
   • Environmental controls including temperature, humidity, and cleanroom compliance
   • Calibration, validation, and maintenance of critical equipment
   • Proper storage conditions for raw materials and finished products
3. Personnel and Training
   • Qualification and competency of personnel involved in production and quality control
   • Frequency and effectiveness of GMP training programs
   • Hygiene practices and adherence to SOPs
4. Process Validation and Control
   • Validation of critical manufacturing processes and analytical methods
   • Scheduled re-validation and ongoing monitoring of production parameters
   • Control of deviations, out-of-specification (OOS) results, and corrective actions
5. Quality Control (QC) and Testing
   • Adequacy of in-process testing and final product release criteria
   • Consistency in sampling methods and analytical testing
   • Documentation of QC results and compliance with pharmacopeial standards
6. Regulatory Compliance
   • Adherence to CDSCO, Schedule M, WHO-GMP, USFDA, EMA, and ICH Q10 requirements
   • History of inspection outcomes and implementation of corrective and preventive actions (CAPA)

Compliance Scoring and Severity Assessment:

• Each parameter is evaluated based on observed deviations in inspection reports and certification records.
• Non-compliance is categorized as High, Moderate, or Low severity, depending on potential impact on product quality and patient safety.
• Quantitative scores and frequency percentages are used to generate tables and charts representing overall GMP adherence across large-scale manufacturers and SMEs.
• By applying these evaluation criteria, the study ensures a standardized, objective, and evidence-based assessment of GMP compliance. This approach allows for meaningful comparisons, identification of systemic gaps, and formulation of actionable recommendations to strengthen quality standards in the Indian pharmaceutical industry.

4. Regulatory Framework for GMP in India

Good Manufacturing Practices (GMP) in India are governed by a robust regulatory framework that ensures the quality, safety, and efficacy of pharmaceutical products. Compliance with GMP is mandatory under national laws and is also aligned with internationally recognized standards to facilitate exports and global trust in Indian medicines.

4.1 Central Drugs and Cosmetics Act (1940) and Rules (1945)

The Drugs and Cosmetics Act, 1940, along with its accompanying rules, serves as the cornerstone of pharmaceutical regulation in India. It mandates licensing, quality control, and manufacturing standards for all pharmaceutical products. The Act requires manufacturers to adhere to conditions that ensure product safety, potency, and purity, including compliance with facility design, equipment standards, and documentation practices.

4.2 Schedule M of the Drugs and Cosmetics Rules

Schedule M, an integral part of the Drugs and Cosmetics Rules, provides detailed guidelines for GMP compliance. It specifies:

• Facility design: Proper layout, adequate space, cleanrooms, and controlled environmental conditions.
• Equipment requirements: Calibration, maintenance, and validation of machinery to ensure consistent product quality.
• Personnel practices: Training, hygiene, and adherence to standard operating procedures (SOPs).
• Documentation and record-keeping: Accurate batch manufacturing records, material traceability, and process validation reports.
• Quality control: Testing protocols, in-process checks, and release criteria.

The Amendment Draft 2023 further strengthens these requirements, emphasizing digital record-keeping, risk-based quality management, and revalidation schedules, bringing Indian standards closer to global GMP norms.

4.3 WHO-GMP Guidelines

India recognizes WHO-GMP standards to facilitate international trade and compliance with global quality benchmarks. WHO-GMP focuses on:

• Preventing contamination and cross-contamination of products
• Ensuring reproducibility and traceability of manufacturing processes
• Maintaining proper documentation and quality management systems
• Risk-based assessment of critical production processes

4.4 International Council for Harmonisation (ICH Q10)

The ICH Q10 pharmaceutical quality system framework is increasingly adopted by Indian manufacturers, particularly those targeting exports. It emphasizes:

• Lifecycle management of pharmaceutical products
• Continuous improvement of quality systems
• Integration of quality risk management into manufacturing practices

4.5 Role of CDSCO and State Drug Regulatory Authorities

The Central Drugs Standard Control Organization (CDSCO), along with State Drug Regulatory Authorities (SDRAs), enforces GMP compliance in India. Their responsibilities include:

• Conducting regular inspections and audits of manufacturing facilities
• Granting manufacturing licenses and certifications
• Monitoring adherence to Schedule M and WHO-GMP guidelines
• Issuing corrective actions, warnings, or penalties for non-compliance

4.6 Harmonization and International Recognition

To enhance the global credibility of Indian pharmaceuticals, the regulatory framework emphasizes harmonization with international GMP standards. Compliance with WHO-GMP, USFDA, EMA, and ICH guidelines enables Indian manufacturers to access regulated markets and meet the expectations of international clients, particularly for export-oriented units.

5. Current Status of GMP Compliance

The current status of Good Manufacturing Practice (GMP) compliance among Indian pharmaceutical manufacturers reflects a heterogeneous landscape, characterized by a significant variation between large-scale enterprises and small to medium-scale enterprises (SMEs). While major corporations have largely achieved international recognition through certifications such as WHO-GMP, USFDA, and EMA, many SMEs face infrastructural, financial, and technical limitations that hinder full compliance.

5.1 GMP Certification Distribution

According to WHO-GMP certification lists, CDSCO reports, and Pharmexcil data (2020–2025), the distribution of GMP-certified units in India is as follows:

• Large-scale enterprises: Approximately 95% of units possess international GMP certification (WHO, USFDA, EMA).
• Medium-scale enterprises: Around 60% hold WHO-GMP or Schedule M certification.
• Small-scale enterprises: Only about 20% have any form of international GMP certification, often limited to Schedule M.

This distribution is visually represented in Figure 3, which demonstrates the proportion of units certified under WHO-GMP, Schedule M, and non-certified categories.

5.2 Common Non-Compliance Findings

Analysis of CDSCO inspection reports and USFDA/EMA inspection findings reveals recurring deficiencies in GMP adherence. Table 1 summarizes the most common non-compliance categories observed between 2020 and 2025:

Table 1: Common GMP Non-Compliance Findings Based on CDSCO Inspections (2020–2025)
(As prepared earlier: Documentation, Equipment & Facilities, Personnel, Validation & Process Control, Quality Control)

Key Observations:

• Documentation lapses (28%) and process validation deficiencies (22%) are the most frequent high-severity deviations.
• Personnel-related non-compliance accounts for 20%, highlighting the importance of continuous GMP training.
• Equipment and quality control deficiencies, while moderate in severity, contribute significantly to overall non-compliance trends.

5.3 GMP Inspection Outcomes

Inspection data from CDSCO, USFDA, and EMA between 2020 and 2025 indicate the following compliance status:

• Fully compliant: 68% of inspected units
• Partially compliant: 22%
• Non-compliant: 10%

5.4 Correlation with Export Performance

Pharmexcil export data further indicate a strong positive correlation between GMP compliance and international market access. Table 2 highlights export performance relative to certification status:

Table 2: Export Performance vs GMP Compliance of Indian Pharmaceutical Units (2020–2025)
(As prepared earlier: Large-scale enterprises dominate global exports with high WHO-GMP compliance; SMEs have limited certification and lower export volumes.)

This relationship emphasizes that GMP adherence is not only critical for domestic quality assurance but also essential for global competitiveness, particularly in regulated markets such as the U.S. and EU.

5.5 Regional and Sectoral Trends

• Regions with a higher concentration of large-scale industries, such as Gujarat, Maharashtra, and Telangana, demonstrate higher compliance levels.
• SMEs located in emerging industrial hubs often exhibit gaps in documentation, process validation, and personnel training, reflecting infrastructural and financial constraints.
• Recent government initiatives, including Schedule M (Amendment Draft 2023) and digital quality management promotion, aim to address these disparities.

6. DISCUSSION

The present analysis of GMP compliance in the Indian pharmaceutical sector reveals a mixed scenario, with notable achievements among large-scale manufacturers and persistent challenges among small and medium enterprises (SMEs). The study integrates data from CDSCO inspections, WHO-GMP certification lists, USFDA and EMA inspection reports, Pharmexcil publications, and peer-reviewed literature to provide a comprehensive perspective on quality standards.

6.1 Large-Scale Enterprises and Global Compliance

Large-scale pharmaceutical companies in India demonstrate high levels of GMP compliance, with approximately 95% holding WHO-GMP or other international certifications. These manufacturers exhibit robust quality management systems, comprehensive documentation practices, validated processes, and well-trained personnel. As highlighted in Figure 3, the dominance of certified units underscores the effectiveness of regulatory oversight and internal quality initiatives in these organizations. Furthermore, export data (Table 2) indicate that high compliance levels are directly associated with greater access to regulated international markets, including the United States, Europe, and Africa.

6.2 SMEs and Compliance Challenges

Despite being critical contributors to domestic production, SMEs face considerable challenges in achieving full GMP compliance. The study identifies recurring deficiencies in documentation, process validation, and personnel training (Table 1). These gaps are reflected in inspection outcomes, where SMEs constitute the majority of partially compliant and non-compliant units (Figure 4). Resource limitations, outdated infrastructure, and limited exposure to international standards are key factors hindering uniform GMP adherence. Addressing these challenges requires targeted training programs, infrastructure modernization, and technology adoption.

6.3 Regional and Sectoral Variations

The analysis reveals regional disparities in GMP compliance. Industrial hubs with a high concentration of large-scale manufacturers, such as Gujarat, Maharashtra, and Telangana, report superior compliance levels. In contrast, emerging pharmaceutical clusters often show gaps in personnel training, environmental controls, and documentation practices. These findings indicate the need for region-specific interventions and enhanced regulatory monitoring, particularly in areas dominated by SMEs.

6.4 Impact of Regulatory Reforms

Recent regulatory initiatives, including Schedule M (Amendment Draft 2023) and the promotion of digital Quality Management Systems (QMS), have the potential to significantly improve compliance. By aligning Indian standards with WHO-GMP and ICH Q10, these reforms address systemic gaps and emphasize risk-based quality management, electronic record-keeping, and process re-validation. The adoption of these reforms is expected to narrow the compliance gap between large-scale enterprises and SMEs, improving both domestic quality assurance and international market access.

6.5 Implications for Policy and Industry

The findings underscore the importance of a holistic approach to GMP compliance that integrates:

• Regulatory enforcement and periodic inspections by CDSCO and State Drug Regulatory Authorities
• Infrastructure upgrades and adoption of modern manufacturing technologies
• Continuous personnel training and capacity building
• Incentives for SMEs to achieve international GMP certification

Strengthening GMP compliance not only safeguards patient safety but also enhances the global credibility of Indian pharmaceuticals, ensuring sustainable growth in both domestic and international markets.

Figure 4: Conceptual Framework for strengthening GMP compliance)